Monitor the company's ability to stabilize operations and achieve revenue growth given the dilutive capital raise, going concern risk, and Nasdaq deficiency. The Series L warrants at $0.65 create potential overhang if the stock trades near that level.
NSPR drugs
NSPR drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InspireMD filed an underwriting agreement for a $37.5M offering of common stock, pre-funded warrants, and Series L warrants, priced at $0.65 per unit. The offering is highly dilutive relative to the current 46.8M shares outstanding and follows a Q3 2026 revenue decline of 11.1% YoY to $2.24M, a net loss of $9.76M, and a going concern risk. Proceeds will fund operations, R&D, and working capital.
Key Financial Metrics
Key Facts
- Offering of 7,342,308 shares, 50,350,000 pre-funded warrants, and 43,269,231 Series L warrants at $0.65 per unit
- Underwriters have option to purchase up to 8,653,846 additional shares and warrants (15% over-allotment)
- Total potential proceeds of $37.5M from the offering
- Pre-funded warrants have exercise price of $0.0001 per share; Series L warrants have exercise price of $0.65 per share
- Offering is highly dilutive relative to 46.8M shares outstanding prior to the offering
- Q3 2026 revenue declined 11.1% YoY to $2.24M, net loss of $9.76M, cash of $19.2M
- Company disclosed a Nasdaq minimum bid price deficiency and a going concern risk
- Proceeds will fund operations, R&D, and working capital
Financial Impact
$37.5M gross proceeds from offering; highly dilutive with potential issuance of up to 101M additional shares (including warrants) vs 46.8M outstanding
Risk Factors
- Extreme dilution: potential issuance of up to 101M additional shares (including warrants) vs 46.8M outstanding
- Going concern risk and Nasdaq minimum bid price deficiency
- Q3 2026 revenue declined 11.1% YoY with net loss of $9.76M
- Series L warrants at $0.65 may create selling pressure if stock trades near exercise price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-051997 |
| Exhibit: ex4-2.htm | 0001493152-26-051997 |
| Exhibit: ex4-1.htm | 0001493152-26-051997 |
| Exhibit: ex4-3.htm | 0001493152-26-051997 |
| Exhibit: ex5-1.htm | 0001493152-26-051997 |
Track record
29 reports on NSPR
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
- Nov 16, 20261d ago 8-K Bearish 6/10 Viewing Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 8-K Bullish 7/10 No price data
- Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers